URGN Covered Call Strategy
URGN (UroGen Pharma Ltd.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN (UroGen Pharma Ltd.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.68B, a beta of 1.62 versus the broader market, a 52-week range of 12.73-36.08, average daily share volume of 798K, a public-listing history dating back to 2017, approximately 291 full-time employees. These structural characteristics shape how URGN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.62 indicates URGN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a covered call on URGN?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current URGN snapshot
As of June 30, 2026, spot at $37.17, ATM IV 87.10%, IV rank 41.24%, expected move 24.97%. The covered call on URGN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this covered call structure on URGN specifically: URGN IV at 87.10% is mid-range versus its 1-year history, so the credit collected on a URGN covered call sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 24.97% (roughly $9.28 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated URGN expiries trade a higher absolute premium for lower per-day decay. Position sizing on URGN should anchor to the underlying notional of $37.17 per share and to the trader's directional view on URGN stock.
URGN covered call setup
The URGN covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With URGN near $37.17, the first option leg uses a $39.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed URGN chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 URGN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $37.17 | long |
| Sell 1 | Call | $39.00 | $1.90 |
URGN covered call risk and reward
- Net Premium / Debit
- -$3,527.00
- Max Profit (per contract)
- $373.00
- Max Loss (per contract)
- -$3,526.00
- Breakeven(s)
- $35.27
- Risk / Reward Ratio
- 0.106
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
URGN covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on URGN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$3,526.00 |
| $8.23 | -77.9% | -$2,704.26 |
| $16.44 | -55.8% | -$1,882.52 |
| $24.66 | -33.7% | -$1,060.78 |
| $32.88 | -11.5% | -$239.05 |
| $41.10 | +10.6% | +$373.00 |
| $49.31 | +32.7% | +$373.00 |
| $57.53 | +54.8% | +$373.00 |
| $65.75 | +76.9% | +$373.00 |
| $73.97 | +99.0% | +$373.00 |
When traders use covered call on URGN
Covered calls on URGN are an income strategy run on existing URGN stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
URGN thesis for this covered call
The market-implied 1-standard-deviation range for URGN extends from approximately $27.89 on the downside to $46.45 on the upside. A URGN covered call collects premium on an existing long URGN position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether URGN will breach that level within the expiration window. Current URGN IV rank near 41.24% is mid-range against its 1-year distribution, so the IV signal is neutral; the covered call thesis on URGN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, URGN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to URGN-specific events.
URGN covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. URGN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move URGN alongside the broader basket even when URGN-specific fundamentals are unchanged. Short-premium structures like a covered call on URGN carry tail risk when realized volatility exceeds the implied move; review historical URGN earnings reactions and macro stress periods before sizing. Always rebuild the position from current URGN chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on URGN?
- A covered call on URGN is the covered call strategy applied to URGN (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With URGN stock trading near $37.17, the strikes shown on this page are snapped to the nearest listed URGN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are URGN covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the URGN covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 87.10%), the computed maximum profit is $373.00 per contract and the computed maximum loss is -$3,526.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a URGN covered call?
- The breakeven for the URGN covered call priced on this page is roughly $35.27 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current URGN market-implied 1-standard-deviation expected move is approximately 24.97%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on URGN?
- Covered calls on URGN are an income strategy run on existing URGN stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current URGN implied volatility affect this covered call?
- URGN ATM IV is at 87.10% with IV rank near 41.24%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.